Innovative 3DP technologies to design personalized medicines have become a new paradigm in the pharmaceutical industry.1 The recent launch of antiepileptic drug Spritam® by Aprecia in 2015, has created immense interest in the... read more

Orally disintegrating tablets (ODT) or sublingual technologies have drawn attention in the industry as a promising approach to deliver drugs in life cycle management to a wide range of the patient population [1-6]. Those ... read more